KBA1412 / Kling Bio, AIM Therap - LARVOL DELTA

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Kling Biotherapeutics B.V. | Recruiting ➔ Completed | N=106 ➔ 16 | Trial completion date: Jan 2025 ➔ Jul 2024 | Trial primary completion date: Jan 2025 ➔ Jul 2024

Combination therapy • Enrollment change • Metastases • Monotherapy • Trial completion • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

KBA1413, an antibody derived from a cured AML patient, recognizes a unique CD43 glycoform shared by AML, MDS and solid cancer cells (ESMO-TAT 2024) - P1 | "ClinicalTrials.gov: NCT05501821. Conclusions Kling Biotherapeutics has discovered several unique cancer targets and their corresponding human antibodies that are currently in preclinical development such as targeting snRNP200 and a novel, truncated form of E-cadherin. KBA1412, a CD9-targeting human antibody is currently being evaluated in a phase 1b dose escalation and dose expansion study in patients with advanced solid tumors."

Clinical • Acute Myelogenous Leukemia • Breast Cancer • Melanoma • Myelodysplastic Syndrome • Oncology • Solid Tumor • CD9 • CDH1 • SPN

Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress (PRNewswire) - "Our lead clinical candidate KBA1412, a unique and previously undiscovered epitope of CD9, is advancing in a Phase 1 study, demonstrating a clean and safe profile in patients with advanced solid tumors. We look forward to sharing data in the foreseeable future and exploring the therapeutic potential of snRNP200 and our uniquely identified CD43 glycoform.'...Poster two, entitled 'snRNP200 reactive antibodies isolated from multiple AML patients show promise for targeted therapy,' details how Kling's proprietary Kling-Select platform has the ability to identify new therapeutic target-antibody pairs to improve patient outcomes by interrogating the B cell repertoire of patients that have achieved remission via a strong tumor-directed immune response...A first-in-human, Phase 1 clinical trial on Kling's first-in-class anti-CD9 antibody in patients with advanced solid malignant tumors is ongoing..."

Preclinical • Trial status • Solid Tumor

Kling Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical trial of KBA1412 in Patients with Advanced Solid Tumors (PRNewswire) - "Kling Biotherapeutics, BV...announces the dosing of the first patient with KBA1412 in its Phase 1b trial...an open-label, multi-center study evaluating the safety, tolerability, PK/PD, and potential efficacy of KBA1412 in adult patients with advanced solid tumors not responding to standard of care....The Phase 1b study will involve dose escalation followed by several expansion cohorts in patients with selected solid tumor types. The expansion cohorts will study KBA1412 alone and in combination with a PD-1 checkpoint inhibitor to further define the dose for future Phase 2 studies and to evaluate secondary endpoints for preliminary assessment of clinical efficacy."

Trial status • Oncology • Solid Tumor

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors (clinicaltrials.gov) - P1 | N=106 | Recruiting | Sponsor: Kling Biotherapeutics B.V.

Combination therapy • Monotherapy • New P1 trial • Melanoma • Oncology • Solid Tumor